| Autor: | J. A. Majka, M. V. Kindt, C. P. Peter |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Gastrointestinal tract
medicine.medical_specialty Physiology business.industry Stomach medicine.medical_treatment Alendronic acid Gastroenterology Etidronic acid Bisphosphonate Pharmacology medicine.anatomical_structure Endocrinology Risedronic acid Internal medicine medicine Gastric mucosa Adverse effect business medicine.drug |
| Zdroj: | Digestive Diseases and Sciences. 43:1009-1015 |
| ISSN: | 0163-2116 |
| DOI: | 10.1023/a:1018826600877 |
| Popis: | Bisphosphonates have generally few clinical adverse effects, the most common being gastrointestinal disturbances. It is generally believed that bisphosphonates with a primary amine are more irritating to the gastrointestinal tract than those without a primary amine. The objective of this study was to compare the gastric irritation potential of an amino bisphosphonate (alendronate) to that of two nonamino bisphosphonates (risedronate and etidronate) in a rat model at pharmacologically equivalent and clinically relevant doses. The doses used were 1, 5, 10, and 30 mg/kg/day for alendronate and risedronate and 40, 200, 400, and 1200 mg/kg/day for etidronate. These doses represent 5-150 times the recommended clinical dose. The drugs were given orally, daily by gavage for four weeks. The gastric irritation potential was assessed by gross and microscopic evaluation of multiple sections of the stomach. This study showed that, at pharmacologically equivalent doses, the gastric irritation potential for alendronate is no greater than that for etidronate or risedronate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink